[ad_1]
And another company is starting the approval process in Switzerland, as the Federal Office of Public Health writes in the press release. The American pharmaceutical company Moderna also wants its vaccine to be approved in Switzerland. This happens in a continuous process.
With continuous evaluation, data can be evaluated as soon as it is available. Companies can submit current data continuously without having to wait for the final results of all studies. That saves valuable time.
More searches in progress
In this way, Swissmedic receives an initial picture of the benefit-risk profile of vaccine candidates before approval studies are completed. “This speeds up evaluation, with the same careful examination of all safety, efficacy and quality requirements,” as BAG emphasizes in the communication. Despite the urgency, it is also important to Swissmedic that all standards are met. To do this, exchange ideas with the authorities of foreign partners.
Moderna works with the mRNA method. The Modernas gene-based vaccine is currently in the hot phase of its testing in the US: In late July, the major phase III clinical study began to verify whether the vaccine actually protects against infection.
Swissmedic is already reviewing the authorization applications for the COVID-19 vaccines from AstraZeneca and Pfizer / BioNTech.
Valais vaccine
Lonza, based in Valais, is Moderna’s manufacturing partner. The production line for the possible vaccine has already been built. Therefore, the corona vaccine could come from the Valais.
